Hassendrini N Peiris1, Roberto Romero2,3,4,5,6,7, Kanchan Vaswani1, Sarah Reed8, Nardhy Gomez-Lopez2,9,10, Adi L Tarca2,9,11, Dereje W Gudicha2,9, Offer Erez2,9,12, Eli Maymon2,9,12, Murray D Mitchell1. 1. Faculty of Health, Centre for Children's Health Research, Institute of Health and Biomedical Innovation, Queensland University of Technology, Brisbane, Australia. 2. Perinatology Research Branch, Division of Obstetrics and Maternal Fetal Medicine, Division of Intramural Research, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, U.S. Department of Health and Human Services, Bethesda, MD, and Detroit, MI, USA. 3. Department of Obstetrics and Gynecology, University of Michigan, Ann Arbor, MI, USA. 4. Department of Epidemiology & Biostatistics, Michigan State University, East Lansing, MI, USA. 5. Center for Molecular Medicine and Genetics, Wayne State University, Detroit, MI, USA. 6. Detroit Medical Center, Detroit, MI, USA. 7. Department of Obstetrics and Gynecology, Florida International University, Miami, FL, USA. 8. UQ Centre for Clinical Research, University of Queensland, Australia. 9. Department of Obstetrics and Gynecology, Wayne State University School of Medicine, Detroit, MI, USA. 10. Department of Biochemistry, Microbiology and Immunology, Wayne State University School of Medicine, Detroit, MI, USA. 11. Department of Computer Science, Wayne State University College of Engineering, Detroit, MI, USA. 12. Division of Obstetrics and Gynecology, Faculty of Health Sciences, Soroka University Medical Center, School of Medicine, Ben Gurion University of the Negev, Be'er Sheva, Israel.
Abstract
OBJECTIVE: To distinguish between prostaglandin and prostamide concentrations in the amniotic fluid of women who had an episode of preterm labor with intact membranes through the utilisation of liquid chromatography-tandem mass spectrometry. STUDY DESIGN: Liquid chromatography-tandem mass spectrometry analysis of amniotic fluid of women with preterm labor and (1) subsequent delivery at term (2) preterm delivery without intra-amniotic inflammation; (3) preterm delivery with sterile intra-amniotic inflammation (interleukin (IL)-6>2.6 ng/mL without detectable microorganisms); and (4) preterm delivery with intra-amniotic infection [IL-6>2.6 ng/mL with detectable microorganisms]. RESULTS: (1) amniotic fluid concentrations of PGE2, PGF2α, and PGFM were higher in patients with intra-amniotic infection than in those without intra-amniotic inflammation; (2) PGE2 and PGF2α concentrations were also greater in patients with intra-amniotic infection than in those with sterile intra-amniotic inflammation; (3) patients with sterile intra-amniotic inflammation had higher amniotic fluid concentrations of PGE2 and PGFM than those without intra-amniotic inflammation who delivered at term; (4) PGFM concentrations were also greater in women with sterile intra-amniotic inflammation than in those without intra-amniotic inflammation who delivered preterm; (5) amniotic fluid concentrations of prostamides (PGE2-EA and PGF2α-EA) were not different among patients with preterm labor; (6) amniotic fluid concentrations of prostaglandins, but no prostamides, were higher in cases with intra-amniotic inflammation; and (7) the PGE2:PGE2-EA and PGF2α:PGF2α-EA ratios were higher in patients with intra-amniotic infection compared to those without inflammation. CONCLUSIONS: Mass spectrometric analysis of amniotic fluid indicated that amniotic fluid concentrations of prostaglandins, but no prostamides, were higher in women with preterm labor and intra-amniotic infection than in other patients with an episode of preterm labor. Yet, women with intra-amniotic infection had greater amniotic fluid concentrations of PGE2 and PGF2α than those with sterile intra-amniotic inflammation, suggesting that these two clinical conditions may be differentiated by using mass spectrometric analysis of amniotic fluid.
OBJECTIVE: To distinguish between prostaglandin and prostamide concentrations in the amniotic fluid of women who had an episode of preterm labor with intact membranes through the utilisation of liquid chromatography-tandem mass spectrometry. STUDY DESIGN: Liquid chromatography-tandem mass spectrometry analysis of amniotic fluid of women with preterm labor and (1) subsequent delivery at term (2) preterm delivery without intra-amniotic inflammation; (3) preterm delivery with sterile intra-amniotic inflammation (interleukin (IL)-6>2.6 ng/mL without detectable microorganisms); and (4) preterm delivery with intra-amniotic infection [IL-6>2.6 ng/mL with detectable microorganisms]. RESULTS: (1) amniotic fluid concentrations of PGE2, PGF2α, and PGFM were higher in patients with intra-amniotic infection than in those without intra-amniotic inflammation; (2) PGE2 and PGF2α concentrations were also greater in patients with intra-amniotic infection than in those with sterile intra-amniotic inflammation; (3) patients with sterile intra-amniotic inflammation had higher amniotic fluid concentrations of PGE2 and PGFM than those without intra-amniotic inflammation who delivered at term; (4) PGFM concentrations were also greater in women with sterile intra-amniotic inflammation than in those without intra-amniotic inflammation who delivered preterm; (5) amniotic fluid concentrations of prostamides (PGE2-EA and PGF2α-EA) were not different among patients with preterm labor; (6) amniotic fluid concentrations of prostaglandins, but no prostamides, were higher in cases with intra-amniotic inflammation; and (7) the PGE2:PGE2-EA and PGF2α:PGF2α-EA ratios were higher in patients with intra-amniotic infection compared to those without inflammation. CONCLUSIONS: Mass spectrometric analysis of amniotic fluid indicated that amniotic fluid concentrations of prostaglandins, but no prostamides, were higher in women with preterm labor and intra-amniotic infection than in other patients with an episode of preterm labor. Yet, women with intra-amniotic infection had greater amniotic fluid concentrations of PGE2 and PGF2α than those with sterile intra-amniotic inflammation, suggesting that these two clinical conditions may be differentiated by using mass spectrometric analysis of amniotic fluid.
Entities:
Keywords:
Chorioamnionitis; eicosanoids; mass spectrometry; parturition; prostamides
Authors: David Metzgar; Mark Frinder; Robert Lovari; Donna Toleno; Christian Massire; Lawrence B Blyn; Raymond Ranken; Heather E Carolan; Thomas A Hall; David Moore; Christian J Hansen; Rangarajan Sampath; David J Ecker Journal: J Clin Microbiol Date: 2013-06-12 Impact factor: 5.948
Authors: Roberto Romero; Piya Chaemsaithong; Steven J Korzeniewski; Juan P Kusanovic; Nikolina Docheva; Alicia Martinez-Varea; Ahmed I Ahmed; Bo Hyun Yoon; Sonia S Hassan; Tinnakorn Chaiworapongsa; Lami Yeo Journal: J Perinat Med Date: 2016-01 Impact factor: 1.901
Authors: R Romero; R Gonzalez; P Baumann; E Behnke; L Rittenhouse; D Barberio; D B Cotton; M D Mitchell Journal: Prostaglandins Leukot Essent Fatty Acids Date: 1994-02 Impact factor: 4.006
Authors: R Romero; M Mazor; F Brandt; W Sepulveda; C Avila; D B Cotton; C A Dinarello Journal: Am J Reprod Immunol Date: 1992 Apr-May Impact factor: 3.886
Authors: Jose Galaz; Roberto Romero; Yi Xu; Derek Miller; Dustyn Levenson; Robert Para; Aneesha Varrey; Richard Hsu; Anna Tong; Sonia S Hassan; Chaur-Dong Hsu; Nardhy Gomez-Lopez Journal: J Perinat Med Date: 2020-09-25 Impact factor: 1.901
Authors: Roberto Romero; Percy Pacora; Juan Pedro Kusanovic; Eunjung Jung; Bogdan Panaitescu; Eli Maymon; Offer Erez; Susan Berman; David R Bryant; Nardhy Gomez-Lopez; Kevin R Theis; Gaurav Bhatti; Chong Jai Kim; Bo Hyun Yoon; Sonia S Hassan; Chaur-Dong Hsu; Lami Yeo; Ramiro Diaz-Primera; Julio Marin-Concha; Kia Lannaman; Ali Alhousseini; Hunter Gomez-Roberts; Aneesha Varrey; Angel Garcia-Sanchez; Maria Teresa Gervasi Journal: J Perinat Med Date: 2021-01-26 Impact factor: 2.716
Authors: Eunjung Jung; Roberto Romero; Bo Hyun Yoon; Kevin R Theis; Dereje W Gudicha; Adi L Tarca; Ramiro Diaz-Primera; Andrew D Winters; Nardhy Gomez-Lopez; Lami Yeo; Chaur-Dong Hsu Journal: J Perinat Med Date: 2021-07-07 Impact factor: 2.716